Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies

Publikation: Bidrag til tidsskriftLetterForskningpeer review

DOI

  1. Biomarkers for early detection of kidney disease: a call for pathophysiological relevance

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901-907

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A narrative review of new treatment options for chronic kidney disease in type 2 diabetes

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Daniël H. van Raalte
  • Petter Bjornstad
  • Hiddo J.L. Heerspink
  • Frederik Persson
  • David Z.I. Cherney
Vis graf over relationer
OriginalsprogEngelsk
TidsskriftKidney International
Vol/bind99
Udgave nummer3
Sider (fra-til)768-770
Antal sider3
ISSN0085-2538
DOI
StatusUdgivet - mar. 2021

Bibliografisk note

Funding Information:
DHvR has acted as a consultant and received honoraria from Boehringer Ingelheim and Lilly, Merck, Novo Nordisk, Sanofi, and AstraZeneca and has received research operating funds from Boehringer Ingelheim-Lilly Diabetes Alliance, AstraZeneca, and Novo Nordisk; all honoraria are paid to his employer (AUMC, location VUMC). PB reports grants, personal fees, and nonfinancial support from AstraZeneca; personal fees from Bayer; personal fees from Bristol Meyer Squibb; grants and personal fees from Boehringer-Ingelheim; personal fees from Eli-Lilly; grants and personal fees from Novo Nordisk; personal fees and nonfinancial support from Sanofi; personal fees from XORT; and grants and personal fees from Horizon Pharma, all outside the submitted work. HJLH is a consultant for AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Pharma, Gilead, Janssen, Merck, Mundi Pharma, Mitsubishi Tanabe, Novo Nordisk, and Retrophin; he has received research support from Abbvie, AstraZeneca, Boehringer Ingelheim, and Janssen. FP reports grants, personal fees, and nonfinancial support from Astra Zeneca; grants, personal fees, and nonfinancial support from Novo Nordisk; personal fees from Boehringer Ingelheim; grants and personal fees from Amgen; personal fees from Novartis; personal fees from MSD; personal fees from Sanofi; personal fees from Eli Lilly; and personal fees from Bayer, all outside the submitted work. DZIC has received honoraria from Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS, Maze, and Novo-Nordisk and has received operational funding for clinical trials from Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, and Novo-Nordisk.

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

ID: 65995912